Integrating real-world evidence (RWE) strategies during drug development and commercialization is critical to maximizing shareholder and stakeholder value. Biopharma executives need to know how to leverage RWE to accelerate clinical development, bolster regulatory strategy, optimize commercialization and market access, and drive down development costs.

By highlighting their recent experiences with concrete examples, panelists will provide insights into how stakeholders, especially regulators, and payers, who are becoming increasingly sophisticated and willing to engage with companies early, are assessing the quality of RWE, whether it is “fit-for-purpose,” and if it can contribute to the “totality of evidence” required for a successful outcome, including a competitive advantage after approval. In particular, the panel will highlight where some companies have been successful and where others have not, and provide some “best practice” thinking on how to integrate and operationalize RWE into their plans.

The experienced consultants at The NemetzGroup act as a seamless extension of biopharma teams, turning strategies into actionable plans and enabling execution through hands-on support. Connect with Marnie Hoolahan and Kristin Owens while you’re in San Diego to learn more about how The NemetzGroup can provide flexible, custom commercialization support to keep your company moving forward with confidence in your mission to serve patients.

Biopharma leaders rely on The NemetzGroup’s deep in-house commercialization and medical affairs experience to craft a holistic approach to knowing what to do, when, and why. In the ever-changing biopharma landscape, the flexible, custom support of The NemetzGroup keeps companies moving forward with confidence in their mission to serve patients. Connect with Senior Consultant Ray Mankoski, MD, PhD while you’re in Chicago to learn more about how The NemetzGroup can help bring your cancer drug to life.